Literature DB >> 8770502

A comparison of electrochemiluminescence and flow cytometry for the detection of natural latex-specific human immunoglobulin E.

L Kobrynski1, L Tanimune, N A Pawlowski, S D Douglas, D E Campbell.   

Abstract

In vitro correlates of type 1 hypersensitivity to natural latex (NL) proteins continue to be limited by both sensitivity and specificity. Methods which have detection limits in the picogram range, namely, radioallergosorbent assays (RAST) and enzyme-linked immunosorbent assays (ELISA), are inadequate for the identification of NL hypersensitivity in certain at-risk groups, such as health care workers. A flow cytometry assay (FCA), previously shown to be comparable to RAST and ELISA in the identification of NL-sensitized pediatric patients with spina bifida, was compared with electrochemiluminescence (ECL) in the evaluation of pediatric patients with spina bifida and NL-sensitized adult health care workers. As with RAST and ELISA, ECL is capable of detecting picogram amounts of specific analyte. The ECL assay detected NL-specific immunoglobulin E (NL-IgE) in three of six health care workers with strong histories of NL hypersensitivity. All six patients were negative by FCA. Further, 2 of 11 spina bifida patients found to be NL-IgE negative by FCA were NL-IgE positive by ECL. These findings suggest that in sensitivity the ECL assay is an improvement over the FCA for the identification of NL-sensitive individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770502      PMCID: PMC170245          DOI: 10.1128/cdli.3.1.42-46.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  15 in total

1.  Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics.

Authors:  G F Blackburn; H P Shah; J H Kenten; J Leland; R A Kamin; J Link; J Peterman; M J Powell; A Shah; D B Talley
Journal:  Clin Chem       Date:  1991-09       Impact factor: 8.327

2.  Synthetic peptide homologous to the envelope proteins of retroviruses shares a cross-reacting epitope with the CD4 receptor.

Authors:  J Rothmann; N F Hassan; D E Campbell; N Kamani; S D Douglas
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

3.  Latex antigens.

Authors:  J E Slater; S K Chhabra
Journal:  J Allergy Clin Immunol       Date:  1992-03       Impact factor: 10.793

4.  IgE reactivity to 14-kD and 27-kD natural rubber proteins in latex-allergic children with spina bifida and other congenital anomalies.

Authors:  H Alenius; T Palosuo; K Kelly; V Kurup; T Reunala; S Mäkinen-Kiljunen; K Turjanmaa; J Fink
Journal:  Int Arch Allergy Immunol       Date:  1993       Impact factor: 2.749

5.  Comparison of diagnostic methods in latex surgical glove contact urticaria.

Authors:  K Turjanmaa; T Reunala; L Räsänen
Journal:  Contact Dermatitis       Date:  1988-10       Impact factor: 6.600

6.  Characterization of latex antigen and demonstration of latex-specific antibodies by enzyme-linked immunosorbent assay in patients with latex hypersensitivity.

Authors:  V P Kurup; K J Kelly; A Resnick; N K Bansal; J N Fink
Journal:  Allergy Proc       Date:  1992 Nov-Dec

7.  Hypersensitivity to natural latex.

Authors:  D Spaner; J Dolovich; S Tarlo; G Sussman; K Buttoo
Journal:  J Allergy Clin Immunol       Date:  1989-06       Impact factor: 10.793

8.  Flow cytometric measurement of immunoglobulin E to natural latex proteins.

Authors:  P L Kwittken; N A Pawlowski; S K Sweinberg; S D Douglas; D E Campbell
Journal:  Clin Diagn Lab Immunol       Date:  1994-03

9.  Skin and serologic testing in the diagnosis of latex allergy.

Authors:  K J Kelly; V Kurup; M Zacharisen; A Resnick; J N Fink
Journal:  J Allergy Clin Immunol       Date:  1993-06       Impact factor: 10.793

10.  Immunoglobulin E reactivity to latex antigens in the sera of patients from Finland and the United States.

Authors:  V P Kurup; K J Kelly; K Turjanmaa; H Alenius; T Reunala; T Palosuo; J N Fink
Journal:  J Allergy Clin Immunol       Date:  1993-06       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.